Pankonin Mark S, Sohi Jasloveleen, Kamholz John, Loeb Jeffrey A
Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201 , USA.
Brain Res. 2009 Mar 3;1258:1-11. doi: 10.1016/j.brainres.2008.12.047. Epub 2008 Dec 29.
The neuregulins are a family of polypeptide factors implicated in a wide range of neurological and psychiatric disorders including multiple sclerosis, schizophrenia, and Alzheimer's disease. Many alternatively-spliced forms of the NRG1 gene are released as soluble factors that can diffuse to near and distant sites within the nervous system where they can accumulate through binding to highly specific heparan-sulfate proteoglycans in the extracellular matrix. Here we have determined the sites of synthesis and accumulation of heparin-binding neuregulin forms in human neocortex, white matter, cerebral spinal fluid, and serum by immunostaining and measurement of neuregulin activity. While neuregulin precursors are expressed predominately within cortical neurons, soluble neuregulin accumulates preferentially on the surface of white matter astrocytes. Consistently, neuregulin activity can be released from the extracellular matrix of human brain by protease treatment. Neuregulin activity is also detectable in human cerebral spinal fluid where its expression appears to be altered in neuronal disorders. While cerebral spinal fluid neuregulin levels were unaltered in patients with multiple sclerosis, they were slightly reduced in amyotrophic lateral sclerosis and Parkinson's disease (p<0.15), but significantly increased in Alzheimer's disease (p<0.01). While not detected in human serum, a novel neuregulin antagonist activity was identified in human serum that could have prevented its detection. These results suggest that human neuregulin is selectively targeted from cortical neurons to white matter extracellular matrix where it exists in steady-state equilibrium with cerebral spinal fluid where it has the potential to serve as a biological marker in human neuronal disorders.
神经调节蛋白是一类多肽因子,与多种神经和精神疾病有关,包括多发性硬化症、精神分裂症和阿尔茨海默病。NRG1基因的许多可变剪接形式以可溶性因子的形式释放,这些因子可以扩散到神经系统内的近端和远端位点,在那里它们可以通过与细胞外基质中高度特异性的硫酸乙酰肝素蛋白聚糖结合而积累。在这里,我们通过免疫染色和神经调节蛋白活性测量,确定了肝素结合型神经调节蛋白在人类新皮层、白质、脑脊液和血清中的合成和积累位点。虽然神经调节蛋白前体主要在皮质神经元内表达,但可溶性神经调节蛋白优先在白质星形胶质细胞表面积累。一致地,蛋白酶处理可以从人脑的细胞外基质中释放神经调节蛋白活性。在人类脑脊液中也可检测到神经调节蛋白活性,其表达在神经元疾病中似乎发生了改变。虽然多发性硬化症患者的脑脊液神经调节蛋白水平未改变,但在肌萎缩侧索硬化症和帕金森病患者中略有降低(p<0.15),而在阿尔茨海默病患者中显著升高(p<0.01)。虽然在人血清中未检测到,但在人血清中鉴定出一种新型神经调节蛋白拮抗剂活性,这可能阻止了其检测。这些结果表明,人类神经调节蛋白从皮质神经元选择性地靶向白质细胞外基质,在那里它与脑脊液处于稳态平衡,在脑脊液中它有可能作为人类神经元疾病的生物标志物。